Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma

Arndt Vogel • 29 Sep 2019
ESMO 2019
Bile Duct Cancer Gastrointestinal Cancer Pemigatinib
FIGHT-202

Arndt Vogel, MD, PhD, Hannover Medical School, Hannover, Germany, discusses the FIGHT-202 study (EudraCT: 2016-002422-36) of pemigatinib in patients with previously treated locally advanced or metastatic cholangiocarcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Arndt Vogel

2:17
The role of the PLATON Network in enhancing precision oncology
Arndt Vogel • 3 Jul 2023
3:14
RATIONALE-301: elderly subgroup analysis of tislelizumab in HCC
Arndt Vogel • 3 Jul 2023
2:27
Advances in FGFR inhibition for hepatobiliary cancer
Arndt Vogel • 3 Jul 2023
0:39
Analysis of the European/North American subgroup in the RATIONALE-301 trial
Arndt Vogel • 3 Jul 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals